Submissions from 2026
Effect of Timely Immunizations on Infection-Related Outcomes after Cll-Directed Treatment, Abdel-Azez Abu-Samak, Marcel Addis-Jackson, Sunita Ghosh, Kylie Springer, Jahnavi Ethakota, Rand Al-Adayleh, and Vijaya Donthireddy
Patient-reported outcomes with acasunlimab monotherapy and in combination with pembrolizumab: Results from a phase II study of PD-L1+ mNSCLC, J. G. Aerts, B. Besse, W. Theelen, D. M. Kowalski, G. Quere, Shirish M. Gadgeel, X. Zhou, Y. Zhou, M. J. Chisamore, M. Holst Mørch, A. Chekalova, and V. Joish
Proactive management of immune-related hepatic events in a phase II trial of acasunlimab plus pembrolizumab in patients with mNSCLC, J. G. Aerts, L. Paz-Ares, B. Besse, C. F. A Helissey, A. Araújo, D. M. Kowalski, G. Quere, J. C. Benitez, F. Guisier, W. Theelen, F. Cappuzzo, Shirish M. Gadgeel, T. C. Wehler, M. J. Chisamore, T. Mark, Y. Zhou, T. J. Ong, and E. Felip
Low -neurovirulence wild-type Zika virus strains induce durable tumor regression and survival benefit in patient-derived glioblastoma models, Parvez Akhtar, Samuel Zwernik, Deb Donohoe, Stephen Whitehead, and Richard Rovin
Real-World Outcomes in Gastrointestinal Cancer Patients with Targetable Genomic Alterations Identified on Serial Liquid Biopsy, Linda Albusoul, Lauren Welch, Matthew Margolis, Zaid I. Al Saheli, Gazala Khan, Philip A. Philip, and Maria Diab
Longitudinal on-Treatment Plasma Microrna Profiling for Identification of Biomarker Signatures Associated with Gemcitabine/Nab-Paclitaxel Therapy in Pancreatic Ductal Adenocarcinoma, Mohammed N. Al Hallak, Bin Bao, Husain Y. Khan, Amro Aboukameel, Mandana Kamgar, Abdulghani Sankari, Susan E. Lyons, Shoshana Rothstein, Gregory Dyson, Yin Wan, Yang Shi, Hugo Jimenez, Ramzi Mohammad, M. Wasif Saif, Anthony F. Shields, Boris Pasche, Philip A. Philip, and Asfar S. Azmi
A Novel Epithelial Tumor Signature Predicts Survival and Response to PD-1 Blockade in Non-Small Cell Lung Cancer, Muaath Alsufi, Jehad Yasin, Muthafar Alsufi, Osama Younis, Amro Assayed, and Fawzi Abu Rous
Pretreatment Ct-Based Radiomics and Machine Learning Models for Predicting Treatment Response in Lung Cancer: A Diagnostic Test Accuracy Meta-Analysis, Muhammad Arham, Hanzala Jehangir, Hamza Hameed, Muhammad Ibrahim, Abdel-Azez Abu-Samak, Kinza Bakht, Deevyashali Parekh, Manahil Shafique, Jawad Ahmed, Manas Pustake, Ahmed B. Sukhera, and Gerardo Capo
Effect of Preoperative Breast MRI Staging on Local Regional Recurrence (LRR) in Early Stage Breast Cancer: Alliance A011104/ACRIN 6694, I. Bedrosian, K. Ballman, L. M. McCall, C. E. Comstock, G. W. Unzeitig, T. Yen, A. Weiss, B. G. Haffty, Jessica M. Bensenhaver, S. M. DeSnyder, J. J. Liu, A. H. Partridge, L. A. Carey, and K. K. Hunt
Effect of Preoperative Breast Mri Staging on Detection of Contralateral Breast Cancer (Cbc): Alliance A011104/Acrin 6694, I. Bedrosian, K. Ballman, L. Mccall, G. Unzeitig, T. Yen, A. C. Weiss, B. Haffty, Jessica Bensenhaver, S. DeSynder, J. Liu, A. H. Partridge, L. A. Carey, and K. K. Hunt
Influence of Ptcy on Lymphopenia Following Allogeneic Hematopoietic Stem Cell Transplantation, Yasmeen Berry, Alec McKheen, Zachary Neme, Mahmoud Alhourani, Josephine Emole, Muneer H. Abidi, Edward Peres, Asif Alavi, and Shatha Farhan
Therapeutic Implications of Concurrent ESR1 and PI3K Pathway Mutations in HR+/HER2-Metastatic Breast Cancer, Kimberly Boldig, Sunita Ghosh, and Vrushali Dabak
Stage Distribution, Treatment Patterns, and Stage-Specific Survival in Merkel Cell Carcinoma before and after the Immunotherapy Era: A Seer Analysis (2004–2022), Renu B. Boyapati, Sai S. Bandaru, Manzer Ali, Madhu B. Chandra, Hanzala Jehangir, and Susan E. Lyons
Final Overall Survival (Os) and Safety Analysis of the Phase 3 Alex Study of Alectinib Vs Crizotinib in Patients with Previously Untreated, Advanced Alk-Positive (Alk Plus ) Non-Small Cell Lung Cancer (Nsclc), Eva L. Buchmeier, Tony Mok, D. Ross Camidge, Rafal Dziadziuszko, Shirish Gadgeel, Alice T. Shaw, Dong-Wan Kim, Maurice Perol, Rafael Rosell, Parneet Cheema, Darren Lim, Jessica J. Lin, Nick Pavlakis, Jin Seok Ahn, Li Zhang, Volkmar Henschel, Agata Higgerson, Virginia McNally, Tania O. Lohmann, Vlatka Smoljanovic, and Solange Peters
Clinical Characteristics, Treatment Patterns, and Outcomes of Common Solid Tumors in Arab American Patients, Shadi Chamseddine, Yingnan Zhang, Yang Shi, Hadeel Assad, Philip A. Philip, Morhaf Al Achkar, Lawrence Flaherty, Rafic Beydoun, Wael Sakr, Asfar S. Azmi, and Khalil Choucair
Association between Smoking, Tumor Genetics, and Outcomes in Men with Metastatic Prostate Cancer, Christopher Choi, Matthew Labriola, Clara Hwang, Pedro C. Barata, Frank C. Cackowski, Amanda Broderick, Mehmet A. Bilen, Deepak Kilari, Laura Graham, Abhishek Tripathi, Rohan Garje, Vadim S. Koshkin, Tanya B. Dorff, Michael T. Schweizer, Rana R. McKay, Zachery R. Reichert, Alexandra Sokolova, Catherine H. Marshall, and Andrew J. Armstrong
Activity and biomarker analyses with casdatifan (cas), a next-generation HIF-2α inhibitor, in refractory clear cell renal cell carcinoma (ccRCC): Results from ARC-20, Toni K. Choueiri, Jaime R. Merchan, Amita Patnaik, Alexandra Drakaki, Brian I. Rini, Sun Young Rha, Jae Lyun Lee, Moshe C. Ornstein, Rohit Kumar, Clara Hwang, Yusra F. Shao, Se Hoon Park, Pedro C. Barata, Jianfen Chen, Ben Weeder, Hunter Cole, Deepti M. Warad, Paul G. Foster, Yinghui Guan, and Rana R. McKay
Randomized Phase Ii Trial of Olaparib and Pembrolizumab Vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline Brca1 or Brca2 (Gbrca1/2) Mutations: Swog S2001, Vincent Chung, Katherine A. Guthrie, Michael J. Pishvaian, Andrew M. Lowy, Davendra Sohal, Sarah Colby, Kim A. Reiss, Gazala Khan, Rafael Winograd, Jeffrey A. Meyerhardt, Eileen M. O'Reilly, E. Gabriela Chiorean, and Philip A. Philip
Delayed Onset of Chronic GVHD in Patients Receiving RGI-2001 Prophylaxis: A Multicenter Phase 2b Study with Comparison to CIBMTR Matched Cohort Data, Zachariah DeFilipp, Yi-Bin Chen, Hannah K. Choe, Yvonne Efebera, Ayman Saad, Shatha Farhan, Lazaros J. Lekakis, Jean A. Yared, Gary J. Schiller, Markus Y. Mapara, Amer Assal, Dana D. Lee, and Hayley Lane
Outcomes of Combined Hcc-Cholangiocarcinoma with Adjuvant Chemotherapy: An Ncdb Cohort, Maria Diab, Sunita Ghosh, Zaid I. Al Saheli, Gazala Khan, Ahmed Nassar, and Philip A. Philip
Sacituzumab govitecan in combination with capecitabine for the treatment of advanced gastrointestinal cancers after progression on standard therapy, Maria Diab, Sunita Ghosh, Gazala Khan, Zaid I. Al Saheli, Ira S. Wollner, and Philip A. Philip
Outcomes with Adjuvant Chemotherapy in Patients with Early-Stage Biliary Tract Cancers: An Ncdb Analysis, Maria Diab, Karim Koussa, Zaid I. Al Saheli, Gazala Khan, David S. Kwon, and Philip A. Philip
Advanced pancreatic adenocarcinoma outcomes in patients with DDR deficiencies outside of BRCA1/2 and PALB2, Maria Diab, Brooke Rhead, Matina Fragkogianni, Zaid I. Al Saheli, Gazala Khan, Ira S. Wollner, Parag Parikh, David S. Kwon, and Philip A. Philip
Integrating Artificial Intelligence to Evaluate Outcomes and Disparities in Young-Onset Breast Cancer: A Seer-Based Retrospective Cohort Study, Jahnavi Ethakota, Palak Grover, Fnu Sonam, Danesh Kumar, and Devin B. Malik
Trends in hepatocellular carcinoma (HCC) incidence and impact of hepatitis C antiviral therapy: A population-based subgroup analysis, Jahnavi Ethakota, Palak Grover, Fnu Varsha, Bipneet Singh, Danesh Kumar, and Devin B. Malik
Post-Transplant Cyclophosphamide and Urinary-Derived Human Chorionic Gonadotropin and Epidermal Growth Factor (uhCG/EGF) As Graft Versus Host Disease Prophylaxis for Mismatched Unrelated Donor Transplantation: A Phase I Dose Escalation Study (PTCY2HCG3), Shatha Farhan, Edward Peres, Josephine Emole, Asif Alavi, and Muneer H. Abidi
Investigating the Influence of Genetic Background on TNBC-T Cell Interactions in TNBC Organoids and Co-Cultures, Batoul Farran, Moses Kamita, Shuk Mei Wong, Sylvester Antwi, Valerie O. Aboah, Harriet Larrious-Lartey, Jessica M. Bensenhaver, Haythem Ali, Eleonor Walker, Foster Amponsah, Josephine Nsafu, Rose Dampson, Patrick K. Akapko, and Evelyn Jiage
Global First-in-Human (FiH) Monotherapy Dose Escalation Trial of BAY2862789, a Diacylglycerol Kinase Alpha (DGKα) Selective Intra-Cellular T Cell Checkpoint Inhibitor in Solid Tumors, Ravit Geva, Ofra Maimon, Aaron Hansen, Jeong Eun Kim, Javier Garcia-Corbacho, Enriqueta Felip, Sook Hee Hong, Kyriakos Papadopoulos, Guru Sonpavde, Alexandre Desjonqueres, Yulin Li, Christoph Mancao, Jochen Schulze, Stephen Ducray, Andrea Frohwann, Lidia Sacchetto, Huijuan Su, Laura Hunt, Stefanie Reif, David A. Schaer, Helge Roider, Leila Khoja, Shirish M. Gadgeel, and Tae Min Kim
A Comparison of Clinical Features and Treatment Outcomes in Breast Cancer Leptomeningeal Metastasis between African American and Caucasian Populations: A Single Institution Experience, Bipin Ghimire, Lisa R. Rogers, and Marian Girgis
Efficacy of Systemic Therapy in HER2-Low Breast Cancer with CNS Metastases: A "Real-World" Experience, Bipin Ghimire, Lisa R. Rogers, and Marian Girgis
Safety and Performance Results from Pathfinder 2, a Registrational Study of a Multi-Cancer Early Detection (Mced) Test in an Intended-Use Population, Karthik Giridhar, Charles H. McDonnell III, Dax Kurbegov, Marc R. Matrana, Shirish M. Gadgeel, Raymond Kim, Gretchen Stipec, Kevin C. Oeffinger, Michael J. Demeure, James W. Lillard, Rebecca Davidson Kaltman, Jennifer Tran, Alan Roth, Sami Tahhan, Andrew S. Poklepovic, Donald A. Richards, Rita Lopatin, Celine Marquez, Margaret E. McCusker, and Nima Nabavizadeh
A Phase 2 Trial of (Z)-Endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women with Er+, Her2-, Breast Cancer (Evangeline), M. P. Goetz, V. J. Suman, C. Lopez, H. Erickson, L. Beaulieu, S. S. Hammer, L. Mina, R. Leon-Ferre, K. N. Hunt, M. Piltin, A. Degnim, J. N. Ingle, J. C. Boughey, B. A. Sarah, J. M. Reid, M. Schellenberg, J. R. Hawse, P. Advani, K. Giridhar, F. Batalini, D. Flora, J. M. Jones, N. A. Bagegni, J. Jakub, V. Abramson, Vrushali Dabak, W. J. Irvin, E. Sima, K. Seema, and S. C. Quay
A Phase 1/2 Study of Ep0062 (Vosilasarm), a First-in-Class Oral Selective Androgen Receptor Modulator (Sarm), in Combination with Standard-of-Care Endocrine Therapy +/- Targeted Therapies in Patients with Advanced or Metastatic Ar+/Er+/Her2− Breast Cancer, Rafael Grochot, Hyo S. Han, Meritxell Bellet, Erika P. Hamilton, Rodrigo Sanchez-Bayona, Valentina Boni, Patricia LoRusso, Carlo Palmieri, Hendrik-Tobias Arkenau, Anne C. Armstrong, Marian Girgis, Neelima Vidula, Hannah van den Boomen, and Joyce O'Shaughnessy
Diagnostic Accuracy of Frozen Sections for Intraoperative Detection of Spread through Air Spaces in Early-Stage Lung Cancer: Systematic Review and Meta-Analysis, Hamza Hameed, Hanzala Jehangir, Muhammad Arham, Manahil Shafique, Abdullah Jehangir, Aquiles De Leon Javier, Muhammad Uzair, Deevyashali Parekh, Abdel-Azez Abu-Samak, Manas Pustake, and Gerardo Capo
Outcomes of Inferior Vena Cava Filters in Breast Cancer Patients with Dvt: National Inpatient Sample–Based Comparative Analysis, Oluchi Idenyi, Madhu B. Chandra, Veera D. V Kurra, Veera D. S Kurra, Vishwanath Anil, and Onyekachi Anya
Flu/Mel/TBI Peripheral Blood Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide and Bortezomib (Cy2Bor3): A Pilot Study, Adnan Khan, Xuan Ma, Edward Peres, Asif Alavi, Josephine Emole, Muneer H. Abidi, and Shatha Farhan
Preclinical Evaluation of a Novel Hyperbolic NAMPT Inhibitor in Combination with Pan-RAS Targeted Therapies in Pancreatic Ductal Adenocarcinoma, Husain Y. Khan, Mohammed N. Al Hallak, Sahar F. Bannoura, Md Hafiz Uddin, Bin Bao, Mohamad W. Sukkari, Adeeb Aboukameel, Khalil Choucair, Hugo Jimenez, Grayson Barker, Callum McGrath, Ganji Purnachandra Nagaraju, Rafic Beydoun, Yang Shi, Philip A. Philip, Azeddine Atfi, Bassel El-Rayes, Ramzi M. Mohammad, Min Wu, Michael Schelle, Boris C. Pasche, and Asfar S. Azmi
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-North America), Christopher Lieu, Guan Yu, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Ibrahim Halil Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Arvind Dasari
Zidesamtinib in Patients with ROS1+NSCLC Previously Treated with Repotrectinib or Taletrectinib, Geoffrey Liu, Alexander E. Drilon, Benjamin Besse, Gianluca Spitaleri, Jessica J. Lin, Byoung Chul Cho, Tatsuya Yoshida, Daniel Haggstrom, Steven Kao, Aurelie Swalduz, Misako Nagasaka, Benjamin J. Solomon, Lorenza Landi, Chiara Bennati, Elvire Pons-Tostivint, Christophe Dooms, A. J. van der Wekken, Saiama Waqar, Shirish M. Gadgeel, Chia-Chi Lin, Tetsuro Kondo, Hidetoshi Hayashi, Daniel Tan, Giulia Pasello, Matteo Duca, Luis G. Paz-Ares, Antonio Calles, Enriqueta Felip, Julien Mazieres, and Adrianus J. de Langen
Supporting Staff When Patients Cry for Help: Provider Satisfaction With a Cancer-Specific Mental Health Crisis Line, Taisel Losada-Bekou, Kellie Martens, Eve DePascale, Michael Ryan, Camille Romain, and Olga Slavin-Spenny
First-Line Odronextamab (Odro) Plus Chemotherapy (Chop) in Diffuse Large B-Cell Lymphoma (Dlbcl): Olympia-3 Part 1b Results, Matthew Matasar, Thomas A. Jandl, Rita Assi, Philip Kuriakose, Chait Iragavarapu, Thomas Illmer, Neta Goldschmidt, Abraham Avigdor, Youngwoo Jeon, Shin Ong, Costas K. Yannakou, Hanlon Sia, Ho Jin Shin, Lily Wong, Sonia Gonzalez de Villambrosia, Ahlam N. Kori, Ciel De Vriendt, Alice Cao, Nazia Iqbal, and Jean-Marie Michot
Fianlimab (anti-LAG-3) + cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma (Mel): Subgroup analyses by blinded independent central review (BICR), Meredith McKean, Amy M. Weise, Kyriakos P. Papadopoulos, John Crown, Sajeve S. Thomas, Janice Mehnert, John M. Kaczmar, Kevin B. Kim, Nehal J. Lakhani, Melinda L. Yushak, Jayakumar Mani, Fang Fang, Shuquan Chen, Jingxiao Chen, Laura Brennan, JuAn Wang, Israel Lowy, Mark Salvati, Matthew G. Fury, and Jean-Francois Pouliot
TRIB2 as a Therapeutic Vulnerability in ALK-Rearranged Non-Small Cell Lung Cancer, Jitender Monga, Sudha Sadasivan, Sang-Yoon Lee, Sharad K. Suthar, Craig Rogers, and Shirish M. Gadgeel
Swog S2107: Randomized Phase Ii Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Previously Treated Mss, Brafv600e Metastatic Colorectal Cancer (Mcrc), Van K. Morris II, Sarah Colby, Scott Kopetz, Katherine A. Guthrie, William J. Chapin, Rimini Breakstone, Zishuo I. Hu, Marwan Fakih, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, and Philip A. Philip
High-Dose Cryopreserved Bone Marrow from Deceased Donors May Reduce Relapse in HLA-Mismatched Allogeneic Transplantation: Day 180 Post-Transplant HOPE Update, Sagar Munjal, Muneer H. Abidi, Jeremy Pantin, Preethi Prasad, Vicki L. Graves, W. Scott Goebel, and Erik J. Woods
Targeting BCL2 Pathway to Enhance Immunogenicity in ALK Plus NSCLC, Batkhishig Munkhjargal, Sudha M. Sadasivan, Shirish M. Gadgeel, and Amanda Pilling
58P Real-world intracranial effectiveness of sotorasib in second-line (2L) and beyond (2L+) treatment (tx) of KRAS G12C-mutated non-small cell lung cancer (NSCLC) with brain metastases (BM), E. Nadal, J. Sabari, A.-M. C. Dingemans, Shirish M. Gadgeel, J. Lee, J. J. Wolf, H.-W. Ko, R. Gupta, R. Jassim, C. Ardito-Abraham, M. A. Mesa Frias, and S. B. Goldberg
Long-Term Treatment with First-Line Amivantamab Plus Lazertinib: Impact of Treatment Discontinuation, Maintenance, and Early Adverse Event Management on Duration of Therapy, Danny Nguyen, Alexander I. Spira, Hidetoshi Hayashi, Scott Owen, Ernesto Korbenfeld, Jeronimo R. Rodriguez Cid, Claudio Martin, Seema Sethi, Sujay Shah, Andy L. Johnson, Elizabeth Fennema, Yichuan Xia, and Shirish M. Gadgeel
Orbital Cancer: Historical Trends in Histological Composition and Cause-Specific Mortality Based on Seer Database Analysis, Cameron Peres, Jamil Qiqieh, Essam Al-Snayyan, Avery Mendelson, and Susan E. Lyons
Tocilizumab Prophylaxis Following Idecabtagene Vicleucel in the Outpatient Setting in Patients with Relapsed or Refractory Multiple Myeloma, Edward Peres, Shatha Farhan, Josephine Emole, Muneer H. Abidi, Asif Alavi, and Cameron Peres
Appendiceal Cancer: Historical Trends in Histological Composition and Cause-Specific Mortality Based on Seer Database Analysis, Jamil Qiqieh, Cameron Peres, Essam Al-Snayyan, Avery Mendelson, and Susan E. Lyons
Update on Upstaging from Ct1 to Pt2 in Triple-Negative and Her2-Positive Breast Cancer after Implementation of 15mm T1c Threshold for Primary Surgery, Madyson Riddell, Jessica Bensenhaver, Ena Muhamedovic, Hemi Thaker, Christine Joliat, Theresa Schwartz, Anna Lehrberg, Laura Dalla Vecchia, S. David Nathanson, Laura Susick, Lindsay Petersen, and Haythem Ali
Tiktok University: Breast Cancer 101, Madyson Riddell, Anne Patterson, Tarek Araji, Rachel Fan, and Lindsay Petersen
Application of Sound/Insema at a Metropolitan Breast Cancer Program: Who Needs a Sentinel Node Biopsy?, Madyson Riddell, Theresa Schwartz, Anne Patterson, Lindsay Petersen, Anna Lehrberg, Laura Dalla Vecchia, Christine Joliat, and Jessica Bensenhaver
Efficacy and Safety by Tumor Location in the Phase 3 Panova-3 Trial of Tumor Treating Fields (Ttfields) with Gemcitabine/Nab-Paclitaxel in Locally Advanced Pancreatic Adenocarcinoma, Fernando Rivera, Inmaculada Ales Diaz, Emil Lou, Yixing Jiang, Makoto Ueno, and Philip A. Philip
A Phase Ii Study of Amivantamab Hyaluronidase in Met Amplification–Positive Stage Iv or Recurrent Non–Small Cell Lung Cancer (Lung-Map Sub-Study), Christian D. Rolfo, Mary W. Redman, Shirish M. Gadgeel, Katherine Minichiello, Louise Highleyman, Saiama N. Waqar, Roy S. Herbst, Tom Stinchcombe, Kristin A. Higgins, Julie R. Brahmer, Karen L. Reckamp, Hossein Borghaei, Jhanelle E. Gray, and David R. Gandara
Panova-3: Efficacy, Safety and Quality of Life of Tumor Treating Fields ( Ttfields) with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Ductal Adenocarcinoma (La-Pac), Thomas Seufferlein, Vincent Picozzi, Sreenivasa R. Chandana, Bohuslav Melichar, Anup Kasi, Jin Gang, Javier G. Plazas, Andrea J. Bullock, Chun-Yi Hao, Lucjan Wyrwicz, Erika Hitre, Arsen Osipov, Christelle de la Fouchardiere, Inmaculada Ales, Tomislav Dragovich, Woo J. Lee, Kynan Feeney, Philip A. Philip, Makoto Ueno, Eric Van Cutsem, Teresa MacArulla Mercade, and Hani Babiker
Efficacy and Safety of Trifluridine–Tipiracil with Vegf Inhibitors and Egfr Inhibitors in Metastatic Unresectable Colorectal Cancer: A Network Meta-Analysis, Shreya Shambhavi, Harmanjeet Singh, Shubhangi Sharma, Ganesh Ramaprasad, Tanushree Bhatt, and Tiffany Pompa
147TiP BNT326-02: A phase Ib/II trial of BNT326/YL202 (HER3 ADC) with pumitamig (PD-L1 × VEGF-A bsAb) in non-small cell lung cancer (NSCLC), A. Spira, I. V. Bulat, A. Schoenfeld, S. Popat, C. Zhou, M. Erman, A. Greystoke, Shirish M. Gadgeel, J. Rotow, R. Joshi, J. Neal, M. Wermke, S. Ochsenreither, C. K. Lee, M. Wenger, C. Trueck, N. Yang, H. Haliduola, R. Tibes, and X. Le
CXCL9, an Early Inflammatory Marker As Prognostic Indicator Following Allogeneic Stem Cell Transplantation: A Single Prospective cohort study, Swathi Srikantan, Xuan Ma, Asif Alavi, Josephine Emole, Edward Peres, Muneer H. Abidi, and Shatha Farhan
Exploring Potential Predictive Factors for Immunotherapy Response in Early-Stage TNBC: Insights from a Retrospective Analysis, Aroob Sweidan, John Sherwood, Muhammad A. Ahmed, Sakshi Bai, and Haythem Ali
Amino Acid Metabolic Reprogramming Drives Doramectin-Enhanced CD8+ T Cell Immunity and Tumor Control, Sedigheh Taghinezhad-S, Amirhossein Mohseni, Vincenzo Casolaro, Zhongwei Lv, and Dan Li
MTAP-deficient pancreatic adenocarcinoma: Clinical and molecular features, Amer Tamr, Sikander Chohan, Zainab Muslehuddin, Mohammed N. Al Hallak, Maria Diab, Gazala Khan, M. Wasif Saif, Zyad Kafri, Howard Crawford, David S. Kwon, Asfar S. Azmi, and Philip A. Philip
Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis, Haseeb Tareen, Allah Dad, Muhammad Arham, Haris B. Tahir, Priya Kumar, Ahmad Iftikhar, Summiya Nasim, Hafsa Ahmed, Mah Noor, Safi U. Rehman Daim, Muhammad F. Ashraf, Hanzala Jehangir, Anchit Chauhan, Mohammad H. B Abdul Malik, and Susan E. Lyons
Baseline Brain Metastases as a Prognostic Factor in Extensive-Stage Small Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy: A Systematic Review and Meta-Analysis, Haseeb Tareen, Allah Dad, Muhammad Arham, Haris B. Tahir, Priya Kumar, Maria Jamil, Hafsa Ahmed, Misha Khalid, Mohammed D. Marsool, Muhammad M. Sami, Muhammad F. Ashraf, Safi U. Rehman Daim, Rana U. Ahmad, Huzefa Habib, Ahsun R. Siddiqi, and Ahmad Iftikhar
Targeting Xpo1 Reprograms Immune Microenvironment and Confers Sensitivity to Immune Checkpoint Blockade in Pancreatic Ductal Adenocarcinoma, Md Hafiz Uddin, Mohammed N. Al Hallack, Misako Nagasaka, Sahar F. Bannoura, Husain Y. Khan, Amro Aboukameel, Fulya K. Alkan, Hilmi K. Alkan, Khalil Choucair, M. Wasif Saif, Bin Bao, Ibrahim Azar, Eliza W. Beal, Miguel Tobon, Steve Kim, Amr Mohamed, Gregory Dyson, Rafic Beydoun, Ramzi M. Mohammad, Herbert Chen, Bassel F. El-Rayes, Philip A. Philip, Boris C. Pasche, Hasan Korkaya, and Asfar S. Azmi
Targeting NAMPT Using Novel Inhibitor RPT-E-037 in Pancreatic Neuroendocrine Tumor, Md Hafiz Uddin, Husain Y. Khan, Amro Aboukameel, Sahar F. Bannoura, Irfana Muqbil, Hugo Jimenez, Filza Khan, Rafic Beydoun, Gregory Dyson, Yang Shi, Mohammed N. Al Hallack, Nitin Vaishampayan, Ibrahim Azar, Steve Kim, Eliza W. Bael, Miguel Tobon, Khalil Choucair, Walid Sukkari, Hafsa Imtiaz, Herbert Chen, Muhammad W. Saif, Anthony F. Shields, Ramzi M. Mohammad, Philip A. Philip, Bassel F. El Rayes, Min Wu, Michael Schelle, Boris Pasche, and Asfar S. Azmi
First-Line Odronextamab Plus Chop in Diffuse Large B-Cell Lymphoma: Olympia-3 Part 1b Results, Bastian von Tresckow, Matthew Matasar, Thomas Jandl, Rita Assi, Philip Kuriakose, Chaitanya Iragavarapu, Thomas Illmer, Neta Goldschmidt, Abraham Avigdor, Youngwoo Jeon, Shin Yeu Ong, Costas K. Yannakou, Hanlon Sia, Ho-Jin Shin, Lily Wong Lee Lee, Sonia González de Villambrosia Pellón, Ahlam N. Kori, Ciel De Vriendt, Gottfried von Keudell, Sandy Amorim, Gerardo Musuraca, Monica Tani, Eva D. Martin, Antonio G. Garcia, Jurriaan Brouwer-Visser, Katherine Kargus, Hesham Mohamed, Alice Cao, Nazia Iqbal, and Jean-Marie Michot
A Novel Detection Strategy for an Emerging Biomarker: MTAP Loss Detection with Circulating Tumor DNA (CtDNA), Lauren S. Welch, Radhika Gutta, Fawzi Abu Rous, Bindu R. Potugari, Sudha Sadasivan, and Shirish M. Gadgeel
First in Human Phase 1 Study of D3S-002, a Purposely Designed ERK1/2 Inhibitor, in Advanced Solid Tumors with MAPK Pathway Mutations, Yi-Long Wu, Michael Millward, Yanqiao Zhang, Matteo S. Carlino, Xian Wang, Amitesh Roy, Jun Zhang, Jun Zhao, Zhen Wang, Amy Weise, Debora Doroshow, Shaonan Wang, Zifei Fan, Rong Su, Jing Zhang, Jia Wang, Wenqian Wang, Cheng Chen, Qian Chen, Hui Wang, and Zhijian Chen
Frameworks for Improving Comprehensive Biomarker Testing in Nsclc: A Multi-Stakeholder Consensus, Maureen F. Zakowski, Juliana Dierks, David Cobden, Sarika Ogale, Zachary A. Goodman, Angela Inneh, Narjust Florez, Justin F. Gainor, Brendan Heiden, Richard S. P Huang, Edward E. Kadel III, Timothy Larson, Jesse Sussell, Bo Wang, Jun Zhang, Fawzi Abu Rous, Kavitha Beedupalli, Wade T. Iams, Jennifer W. Carlisle, and Emily Cassidy
Genomic Predictors of Response to Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (Mcrpc): A Real-World Analysis from the Promise Registry, Peter D. Zang, Nicholas Henderson, Deepak Kilari, Vadim S. Koshkin, Laura Graham, Alexandra Sokolova, Rohan Garje, Yousef Zakharia, Mehmet A. Bilen, Pedro C. Barata, Clara Hwang, Rana R. McKay, Michael T. Schweizer, Andrew J. Armstrong, Zachery R. Reichert, and Tanya B. Dorff
A Purposefully Designed ERK1/2 Inhibitor Achieving Low-Dose, Pulsatile Target Inhibition for Combination with D3S-001, a New-Generation KRAS G12C Inhibitor, Jing Zhang, Wenqian Wang, Zhiqiang Zheng, Xin Xiong, Shaonan Wang, Jia Wang, Zifei Fan, Hui Wang, Qian Chen, Cheng Chen, Michael Millward, Zhen Wang, Jun Zhao, Jun Zhang, Amy Weise, Rong Su, Zhi Jian Chen, and Yi-Long Wu
Variant Topography of Npm1 Mutations in Acute Myeloid Leukemia, Markie Zimmer, Vikram Dhillon, Jeff Aguilar, Dakshin Padmanabhan, Asmita Shukla, Sushmitha N. Reddy, Sikander Cohan, Nagasai Yalavarthi, Yang Shi, Jay Yang, and Suresh Balasubramanian
Impact of Variant Topography of Npm1 Mutations in Acute Myeloid Leukemia, Markie S. Zimmer, Vikram Dhillon, Jeff J. Aguilar, Dakshin S. Padmanabhan, Asmita Shukla, Sushmitha N. Reddy, Sikander Chohan, Nagasai Yalavarthi, Yang Shi, Jay Yang, and Suresh K. Balasubramanian
Submissions from 2025
Abstract A139: Evaluating knowledge and practice patterns of prostate cancer germline testing among providers within a large health system, Jamie T. Abad, Marielle Cabe, Kyle McElyea, Sunita Ghosh, and Clara Hwang
A HIDDEN FUNGAL TRIGGER: A CASE OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, Jamie T. Abad, Kashmira Wani, Luis Gonzalez Mosquera, and Jawad Sheqwara
Impact of UGT1A1*28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3, Maen Abdelrahim, Gazala Khan, Hassan Hatoum, Alice Zervoudakis, Farshid Dayyani, Li Zhang, Jia Li, Fiona Maxwell, Eileen M. O'Reilly, Zev A. Wainberg, and Mary L. B Peters
Impact of UGT1A1∗28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3, Maen Abdelrahim, Gazala Khan, Hassan Hatoum, Alice Zervoudakis, Farshid Dayyani, Li Zhang, Jia Li, Fiona Maxwell, Eileen M. O'Reilly, Zev A. Wainberg, and Mary L. B Peters
DECEASED DONOR BONE MARROW TRANSPLANT: FIRST EVER HUMAN CASE REPORT of SUCCESSFUL ENGRAFTMENT after INFUSION of A CRYOPRESERVED DECEASED DONOR BONE MARROW in A PATIENT with AML, Muneer Abidi, Josephine Emole, Shatha Farhan, Edward Peres, Asif Alavi, Nancy Mikulandric, Klodiana Neme, Preethi Prasad, Vicki Graves, Erik Woods, W. Scott Goebel, and Sagar Munjal
NON-INFECTIOUS SARCOID-LIKE INFLAMMATORY GRANULOMATOUS CONDITIONS (NSIGC) ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS (ICIS) FOR CANCER: UPDATED RESULTS FROM THE INTERNATIONAL ICARUS CONSORTIUM, Ayesha Aijaz, Arifa Bibi, Unaiza Zaman, Aqsa Ashraf, Jair Bar, Rachel Moskovitz Cohen, Damien Urban, Iddo Vardi, Hira Tanwir, Noha Abdel-Wahab, Mohamed Nuh, Maximilian J. Rost, Fabian Acker, Johannes Kleemann, Hannah Smith, Dwight H. Owen, Kevin Ho, Marc Machaalani, Razane El Hajj Chehade, Toni K. Choueiri, Alicia H. Darwin, Pauline Funchain, Alfred Chung Pui So, Eleni Karapanagiotou, George Santis, Maysa Vilbert, Ross D. Merkin, Kerry L. Reynolds, Roma A. Kankaria, and Douglas B. Johnson
Transcriptomic Profiling Identifies a Prognostic and Predictive Inflammatory Signature in Patients With Lung Adenocarcinoma, A. Al-Bzour, N. Al-Bzour, M. Hashki, Y. Estaitia, O. M. Younis, J. Alrawabdeh, S. Abualinin, B. Ricciuti, and Fawzi Abu Rous
Prediction of Distant Metastasis Using CT/PET-Based q Radiomics in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis, N. N. Al-Bzour, A. N. Al-Bzour, M. N. Samarah, N. R. Othman, B. M. Alsarayrah, T. E. Alzaher, M. Hashki, Y. M. Alajlouni, R. A. Sawafta, O. M. Younis, J. Alrawabdeh, and Fawzi Abu Rous
Prediction of Distant Metastasis Using CT/PET-Based Radiomics in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis, N. N. Al-Bzour, A. N. Al-Bzour, M. N. Samarah, N. R. Othman, B. M. Alsarayrah, T. E. Alzaher, M. Hashki, Y. M. Alajlouni, R. A. Sawafta, O. M. Younis, J. Alrawabdeh, and Fawzi Abu Rous
UNCOVERING SYSTEMIC LUPUS ERYTHEMATOSUS: A RARE PRESENTATION WITH SEVERE PANCYTOPENIA, IDIOPATHIC THROMBOCYTOPENIC PURPURA AND PERICARDIAL EFFUSION, Nour Aldaoud, Ayushi Garg, Vamsi K. Lavu, Joiven Nyongbella, and Wajahat Khan
Treatment outcomes following TME for biologically unfavorable locally advanced rectal cancer, Maryam A. Aleissa, Hussein Gharib, Amr Aref, Amer Zeni, Amer Alame, Ernesto Drelichman, and Jasneet Bhullar
XPO1 inhibition as a clinically viable strategy to enhance durability of response to KRAS G12D inhibitor in pancreatic ductal adenocarcinoma, Mohammed N. Al Hallak, Husain Y. Khan, Amro Aboukameel, Sahar Bannoura, Khalil Choucair, Eliza W. Beal, Miguel Tobon, Rafic Beydoun, Anthony F. Shields, Ramzi Mohammad, Jennifer L. Beebe-Dimmer, Philip A. Philip, Boris Pasche, and Asfar S. Azmi
Evaluating the management of severe anemia in the emergency department: A single-center analysis, Kabeer Ali, Kimberly Boldig, Carmen Smotherman, Brian Li, Jinous Saremian, Walter Quan, and Gabriela Bastidas Mora
Individual participant data meta-analysis comparing neoadjuvant to perioperative chemoimmunotherapy in early-stage non-small cell lung cancer according to PD-L1 status, Jawad Alrawabdeh, Sunita Ghosh, Shahm Raslan, Alessandro Di Federico, Biagio Ricciuti, and Fawzi Abu Rous
Nautilus, a phase 1b/2 trial of combining oral HDAC inhibitor (HDACi) with MEK inhibitor (MEKi) in patients with NRAS-mutated metastatic melanoma (MM), Rodabe N. Amaria, Herbert L. Duvivier, Katy K. Tsai, Parisa Momtaz, Robert W. Galamaga, Evan P. Pisick, Bently P. Doonan, Amy M. Weise, Natalie Langr, James D. Winkler, Harish P. Dave, Jennifer Robinson Diamond, and Ryan J. Sullivan
Nautilus, a phase 1b/2 trial of combining oral HDAC inhibitor (HDACi) with MEK inhibitor (MEKi) in patients with NRAS-mutated metastatic melanoma (MM), Rodabe N. Amaria, Herbert L. Duvivier, Katy K. Tsai, Parisa Momtaz, Robert W. Galamaga, Evan P. Pisick, Bently P. Doonan, Amy M. Weise, Natalie Langr, James D. Winkler, Harish P. Dave, Jennifer Robinson Diamond, and Ryan J. Sullivan
Concurrent KRAS Mutations Render Single-Agent EGFR Inhibitors Futile in Advanced NSCLC, I. Aza, M. Nagasaka, A. Azmi, T. Al Baghdadi, E. Dib, Fawzi Abu Rous, A. Qin, R. Shah, N. Vojjala, K. Goyal, G. Li, J. Quintanilha, J. Altenburg, and R. Graf
The role of artificial intelligence in colorectal cancer and polyp detection: A systematic review, Sakshi Bai, Bipneet Singh, Jahnavi Ethakota, Oboseh J. Ogedegbe, Olanipekun L. Ntukidem, Akshit Chitkara, Sindhu Rani, Danesh Kumar, JoAnn Hirth, and Devin B. Malik
Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC), Pedro C. Barata, Brian Rini, Toni Choueri, Sumanta Pal, Philippe Barthelemy, Roberto Iacovelli, Bradley A. McGregor, Laurence Albiges, Javier Molina-Cerrillo, Benjamin Garmezy, Ralph Hauke, Sheela Tejwani, Arnab Basu, Helen Moon, Katy Beckermann, Moshe Ornstein, Rana McKay, Claudia Lebedinsky, Edgar E. Braendle, and Robert Motzer
Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC), Pedro C. Barata, Brian Rini, Toni Choueri, Sumanta Pal, Philippe Barthelemy, Roberto Iacovelli, Bradley A. McGregor, Laurence Albiges, Javier Molina-Cerrillo, Benjamin Garmezy, Ralph Hauke, Sheela Tejwani, Arnab Basu, Helen Moon, Katy Beckermann, Moshe Ornstein, Rana McKay, Claudia Lebedinsky, Edgar E. Braendle, and Robert Motzer
Biomarker Analysis and Final Efficacy of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer, T. M. Bauer, J.-F. Martini, B. Besse, C.-C. Lin, R. A. Soo, G. J. Riely, F. Toffalorio, D. A. Shepard, S. Y. Liang, P. Hamilton, D. R. Camidge, S. Kao, R. Chiari, Shirish M. Gadgeel, E. Felip, A. T. Shaw, and B. Solomon
In silico evaluation of the interaction of P-gp and 3A4 substrates with the WEE1 inhibitor Debio 0123 and clinical application in the Debio 0123-104 combination trial with carboplatin and etoposide, Anne Bellon, Valentina Gambardella, Luis G. Paz-Ares, Alejandro Navarro, Prantesh Jain, José M. López-Picazo, Maria J. de Miguel, Shirish M. Gadgeel, Sajjad Akbar Bhatti, Pedro Rocha, Alice Ke, Frederic Massiere, Esteban Rodrigo Imedio, and Vito Dozio
In silico evaluation of the interaction of P-gp and 3A4 substrates with the WEE1 inhibitor Debio 0123 and clinical application in the Debio 0123-104 combination trial with carboplatin and etoposide, Anne Bellon, Valentina Gambardella, Luis G. Paz-Ares, Alejandro Navarro, Prantesh Jain, José M. López-Picazo, Maria J. de Miguel, Shirish M. Gadgeel, Sajjad A. Bhatti, Pedro Rocha, Alice Ke, Frederic Massiere, Esteban R. Imedio, and Vito Dozio
The Relationship Among Stage IV Triple Negative Breast Cancer and Regional Lymph Node Metastases, Jenny Bui, S. David Nathanson, Jessica Bensenhaver, Theresa Schwartz, Lindsay Petersen, Anna Lehrberg, Laura Dalla Vecchia, Kylie Springer, and Laura Susick
Phase 1b/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations, David R. Camidge, Nicolas Girard, Shun Lu, Shirish M. Gadgeel, Kristof Cuppens, Se-Hoon Lee, Hidehito Horinouchi, Tae Min Kim, Angelo Delmonte, Elvire Pons-Tostivint, Robert M. Jotte, Nivedita Aanur, Han Coburn, Qi Jiang, Theodore S. Jennaro, Tony Navas, Yan Li, and Jonathan W. Goldman
